z-logo
Premium
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis
Author(s) -
Di Tommaso Luca,
Franchi Giada,
Park Young Nyun,
Fiamengo Barbara,
Destro Annarita,
Morenghi Emanuela,
Montorsi Marco,
Torzilli Guido,
Tommasini Maurizio,
Terracciano Luigi,
Tornillo Luigi,
Vecchione Raffaella,
Roncalli Massimo
Publication year - 2007
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.21531
Subject(s) - glypican 3 , cirrhosis , hepatocellular carcinoma , medicine , gastroenterology , malignancy , pathology
Abstract Hepatocellular nodules in cirrhosis include regenerative (large regenerative, LRN) and dysplastic (low and high grade, LGDN and HGDN) nodules, early and grade 1 HCC (eHCC‐G1), and overt HCC. The differential diagnosis may be particularly difficult when lesions such as HGDN and eHCC‐G1 are involved. We investigated the diagnostic yield of a panel of 3 putative markers of hepatocellular malignancy such as HSP70, glypican 3 (GPC3), and glutamine synthetase (GS). We selected 52 surgically removed nonmalignant nodules (15 LRNs, 15 LGDNs, 22 HGDNs) and 53 HCCs (10 early, 22 grade 1, and 21 grade 2‐3) and immunostained them for HSP70, GPC3, and GS. The sensitivity and specificity of the individual markers for the detection of eHCC‐G1 were 59% and 86% for GS, 69% and 91% for GPC3, and 78% and 95% for HSP70. We identified 2 main phenotypes: (1) all negative, seen in 100% LRN and LGDN, 73% HGDN and 3% eHCC‐G1; (2) all positive, a feature detected in less than half the eHCC‐G1. Using a 3‐marker panel, when at least 2 of them, regardless which, were positive, the sensitivity and specificity for the detection of eHCC‐G1 were respectively 72% and 100%; the most sensitive combination was HSP70+/GPC3+ (59%) when a 2‐marker panel was used. Conclusion: The adopted panel of 3 markers is very helpful in distinguishing eHCC‐G1 from dysplastic nodules arising in cirrhosis. (H EPATOLOGY 2007;45:725–734.)

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here